Glenview Trust co Increases Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• Glenview Trust co increased its stake in Becton, Dickinson and Company by 18.9%, acquiring an additional 13,404 shares during the first quarter, bringing its holdings to 84,277 shares valued at approximately $19.3 million.
• Several analysts have updated their ratings on Becton, Dickinson, with Piper Sandler maintaining a "neutral" rating and a new price target of $200, while Morgan Stanley raised its target to $197 with an "overweight" rating.
• Becton, Dickinson recently announced a quarterly dividend of $1.04 per share, reflecting an annualized dividend yield of 2.2% and a payout ratio of 74.82%.

Glenview Trust co lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,277 shares of the medical instruments supplier's stock after purchasing an additional 13,404 shares during the quarter. Glenview Trust co's holdings in Becton, Dickinson and Company were worth $19,304,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth $26,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth $27,000. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company during the first quarter worth $29,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares in the last quarter. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $3.34 during mid-day trading on Friday, reaching $187.23. 1,118,088 shares of the company's stock were exchanged, compared to its average volume of 1,747,428. The firm has a market capitalization of $53.66 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 1.42 and a beta of 0.27. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a 50-day moving average price of $186.46 and a two-hundred day moving average price of $191.73.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,965 shares of company stock valued at $551,536. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BDX shares. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler restated a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.